{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:09:43Z","timestamp":1780456183622,"version":"3.54.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["110-2314-B-182-039-MY3"],"award-info":[{"award-number":["110-2314-B-182-039-MY3"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG3J1373"],"award-info":[{"award-number":["CMRPG3J1373"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial showed that edoxaban at a very low dosage (VLD) of 15\u00a0mg\/day was more effective than a placebo at preventing stroke\/systemic embolism without significantly increasing the risk of serious bleeding. We aimed to compare the effectiveness and safety for VLD non-vitamin K antagonist oral anticoagulants (NOACs) [edoxaban 15\u00a0mg o.d., dabigatran 110 or 150 o.d., apixaban 2.5\u00a0mg o.d., or rivaroxaban 10\u00a0mg (without the diagnosis of chronic kidney disease) or &amp;lt;10\u00a0mg o.d.] vs. regular-dosage (RD) NOACs (edoxaban 60\/30\u00a0mg o.d. or other labeling-dosage NOACs) among a real-world cohort of elderly atrial fibrillation (AF) population similar to the ELDERCARE-AF cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In this nationwide retrospective cohort study from Taiwan National Health Insurance Research Database (NHIRD), we identified a total of 7294 and 4151 consecutive AF patients aged 80 years or older with a CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke\/transient ischemic attack (2 points) score\u00a0\u22652 who met the enrollment criteria (generally similar to ELDERCARE-AF) taking VLD and RD NOACs from 1 June 2012 to 31 December 2019, respectively. Propensity-score stabilized weighting (PSSW) was used to balance covariates across study groups. Patients were followed up from the first date of prescription for NOACs until the first occurrence of any study outcome, death, or until the end date of the study period (31 December 2020). After PSSW, VLD NOAC was associated with a comparable risk of ischemic stroke\/systemic embolism and major bleeding but a higher risk of major adverse limb events (MALEs) requiring lower limb revascularization or amputation [hazard ratio (HR): 1.54, 95% confidential interval (CI): 1.09\u20132.18; P\u00a0=\u00a00.014), venous thrombosis (HR: 3.75, 95% CI: 1.56\u20138.97; P\u00a0=\u00a00.003), and all-cause mortality (HR: 1.21, 95% CI: 1.15\u20131.29; P\u00a0&amp;lt;0.001) compared with RD NOACs. VLD NOACs showed worse outcomes in most net clinical outcome (NCO) benefits. The main result was consistent based on on-treatment analysis or accounting for death as a competing risk. In general, the advantage of NCOs for the RD NOACs over VLD NOACs persisted in most high-risk subgroups, consistent with the main analysis (P for interaction\u00a0&amp;gt;\u00a00.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Use of VLD NOACs was associated with a greater risk of arterial and venous thrombosis, death as well as the composite outcomes, when compared with that of RD NOAC in high-risk elderly AF patients at increased bleeding risk. Thromboprophylaxis with RD NOAC is still preferable over VLD NOAC for the majority of elderly AF patients at increased bleeding risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad058","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T12:40:18Z","timestamp":1691844018000},"page":"681-691","source":"Crossref","is-referenced-by-count":22,"title":["Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study"],"prefix":"10.1093","volume":"9","author":[{"given":"Yi-Hsin","family":"Chan","sequence":"first","affiliation":[{"name":"The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou , Taoyuan City 33305 , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan City 33302 , Taiwan"},{"name":"School of Traditional Chinese Medicine, College of Medicine, Chang-Gung University , Taoyuan City 33302 , Taiwan"},{"name":"Microscopy Core Laboratory, Chang Gung Memorial Hospital at Linkou , Taoyuan 33305 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-2793","authenticated-orcid":false,"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital , Taipei 112304 , Taiwan"},{"name":"Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-1295","authenticated-orcid":false,"given":"Shao-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan City 33302 , Taiwan"},{"name":"Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University , Taoyuan City , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Fu","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan City 33302 , Taiwan"},{"name":"Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University , Taoyuan City, Taiwan"},{"name":"New Taipei City Municipal Tucheng Hospital (Chang Gung Memorial Hospital , Tucheng Branch), New Taipei City 236017 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ru","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Medicine, Chang Gung University , Taoyuan City 33302 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsin","family":"Yeh","sequence":"additional","affiliation":[{"name":"The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou , Taoyuan City 33305 , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan City 33302 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tai","family":"Kuo","sequence":"additional","affiliation":[{"name":"The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou , Taoyuan City 33305 , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan City 33302 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-8969","authenticated-orcid":false,"given":"Lai-Chu","family":"See","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Medicine, Chang Gung University , Taoyuan City 33302 , Taiwan"},{"name":"Biostatistics Core Laboratory, Molecular Medicine Research Center, Chang Gung University , Taoyuan City 33302 , Taiwan"},{"name":"Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou , Taoyuan City 33305 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool , UK"},{"name":"Department of Clinical Medicine, Aalborg University , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"2023121405273209600_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"2023121405273209600_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023121405273209600_bib3","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-pacific expert consensus paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemost"},{"key":"2023121405273209600_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ehjqcco\/qcab076","article-title":"Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk","volume":"8","author":"Chao","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2023121405273209600_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Chan","year":"2019","journal-title":"Chest"},{"key":"2023121405273209600_bib6","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"key":"2023121405273209600_bib7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"2023121405273209600_bib8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2023121405273209600_bib9","author":"National Health Insurance Administration, Ministry of Health and Welfare, Taiwan"},{"key":"2023121405273209600_bib10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2023121405273209600_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2023121405273209600_bib12","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"2023121405273209600_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2023121405273209600_bib14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2023121405273209600_bib15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2023121405273209600_bib16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"2023121405273209600_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","journal-title":"J Arrhythm"},{"key":"2023121405273209600_bib18","doi-asserted-by":"crossref","first-page":"e013053","DOI":"10.1161\/JAHA.119.013053","article-title":"Comparisons of rivaroxaban following different dosage criteria (ROCKET AF or J-ROCKET AF Trials) in Asian patients with atrial fibrillation","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2023121405273209600_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2023121405273209600_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2023121405273209600_bib21","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"Mccaffrey","year":"2013","journal-title":"Stat Med"},{"key":"2023121405273209600_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"2023121405273209600_bib23","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2023121405273209600_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"2023121405273209600_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.arr.2018.10.006","article-title":"Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation","volume":"49","author":"Kato","year":"2019","journal-title":"Ageing Res Rev"},{"key":"2023121405273209600_bib26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/heartjnl-2016-310358","article-title":"Effects of dabigatran according to age in atrial fibrillation","volume":"103","author":"Lauw","year":"2017","journal-title":"Heart"},{"key":"2023121405273209600_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"2023121405273209600_bib28","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"key":"2023121405273209600_bib29","doi-asserted-by":"crossref","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2023121405273209600_bib30","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1253\/circj.CJ-14-0942","article-title":"Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment","volume":"79","author":"Koretsune","year":"2015","journal-title":"Circ J"},{"key":"2023121405273209600_bib31","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1253\/circj.CJ-21-0399","article-title":"Optimal management of anticoagulation therapy in Asian patients with atrial fibrillation","volume":"85","author":"Cheng","year":"2021","journal-title":"Circ J"},{"key":"2023121405273209600_bib32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.amjcard.2009.10.018","article-title":"Thromboembolism in atrial fibrillation","volume":"105","author":"Menke","year":"2010","journal-title":"Am J Cardiol"},{"key":"2023121405273209600_bib33","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/europace\/euab180","article-title":"Atrial fibrillation and risk of venous thromboembolism: a Swedish Nationwide Registry Study","volume":"23","author":"Hornestam","year":"2021","journal-title":"Europace"},{"key":"2023121405273209600_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jth.12762","article-title":"Atrial fibrillation and future risk of venous thromboembolism:the Tromso study","volume":"13","author":"Enga","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2023121405273209600_bib35","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/heartjnl-2020-316977","article-title":"Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020","volume":"106","author":"Ding","year":"2020","journal-title":"Heart"},{"key":"2023121405273209600_bib36","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023121405273209600_bib37","doi-asserted-by":"crossref","first-page":"e2215580","DOI":"10.1001\/jamanetworkopen.2022.15580","article-title":"Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization","volume":"5","author":"Hess","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023121405273209600_bib38","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2023121405273209600_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan's national health insurance research database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad058\/51307068\/pvad058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/8\/681\/54021863\/pvad058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/8\/681\/54021863\/pvad058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:27:58Z","timestamp":1702531678000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/8\/681\/7242543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,14]]},"published-print":{"date-parts":[[2023,12,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad058","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,8,14]]}}}